Edition:
United States

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

140.00USD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$140.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
112,307
52-wk High
$208.78
52-wk Low
$75.87

Chart for

About

Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.... (more)

Overall

Beta: --
Market Cap(Mil.): $2,616.89
Shares Outstanding(Mil.): 29.85
Dividend: --
Yield (%): --

Financials

  LOXO.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -4.18 -- --
ROI: -31.65 9.01 14.96
ROE: -31.65 10.15 16.52

German stocks - Factors to watch on Nov. 27

BERLIN, Nov 27 The following are some of the factors that may move German stocks on Tuesday:

Nov 27 2018

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.

Nov 26 2018

UPDATE 3-Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

Nov 26 A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.

Nov 26 2018

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

Nov 26 A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation won U.S. approval on Monday, according to the Food and Drug Administration's website.

Nov 26 2018

Swiss stocks - Factors to watch on Oct. 22

ZURICH/BERLIN, Oct 22 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 8,896 points on Monday, according to premarket indications by bank Julius Baer .

Oct 22 2018

German stocks - Factors to watch on Oct. 22

FRANKFURT/BERLIN, Oct 22 - The following are some of the factors that may move German stocks on Monday:

Oct 22 2018

Roche takes on Loxo, Bayer in gene-defined cancer class

MUNICH Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

Oct 21 2018

Roche takes on Loxo, Bayer in gene-defined cancer class

MUNICH, Oct 21 Roche's entrectinib cancer pill was shown to shrink tumours in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.

Oct 21 2018

Bayer open for drug licensing deals, cutting debt remains priority

FRANKFURT Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

Sep 05 2018

Bayer open for drug licensing deals, cutting debt remains priority

FRANKFURT, Sept 5 Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

Sep 05 2018

Earnings vs. Estimates